United States Vaccine Market Size

United States vaccines market is set to surpass US$ 21 Billion threshold by 2025.
“United States Vaccines Market 2015 – 2025: Top 21 Vaccines Analysis, Deal Trends, Players and Forecasts” presents an in-depth assessment of the United States vaccines market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook for United States vaccines market. The report includes historic data from 2015 to 2017 and forecasts until 2025.
The report contains a granular analysis of the present industry situations, market demands, reveal facts on the market size, revenues and provides forecasts through 2025.The report provides clear insight into current and future developments of the United States vaccines market. The report also explores detailed analysis of top 21 vaccines market assessment in United States from 2015 to 2017 and forecasts to 2025. The report also details the latest information about the vaccines pricing trends and regulatory landscape in United States.
Additionally, the report includes assessment of promising vaccines in the clinical development by major companies. Key trends in terms of collaboration, merger & acquisition, distribution, exclusive and licensing agreement are analyzed with details. The report also explores detailed description of growth drivers and inhibitors of the United States vaccines market.
The report concludes with the profiles of major players in the United States vaccines market. The key market players are evaluated on various parameters such as business overview, promising vaccines in the clinical development and recent development.
The major companies dominating this market for its products, services and continuous product developments are:
 
Pfizer, Merck, Sanofi Pasteur and GlaxoSmithKline(GSK)
Top 21 Vaccines Covered Under This Report Are:
 
Prevnar/Prevnar 13
Gardasil/Gardasil 9
Fluzone
Varivax
Menactra
Proquad
Pneumovax
FluLaval/Fluarix
Havrix/Twinrix/Engerix-B
MMR II
Adacel
Boostrix
Bexsero
Menveo
Trumenba
Shingrix
Pentacel
Recombivax HB
Rotateq
Rotarix
Pediarix/Infanrix
The Latest Industry Data Included in this Report:
United States Vaccines Market Size & Analysis (2015 – 2025)
United States Vaccines Market Share & Y-o-Y Growth (%), 2015 – 2025
United States Top 21 Vaccines Market Assessment & Opportunity (2015 – 2025)
United States Vaccines Pricing Trends & Analysis
United States Vaccines Regulatory System
Major Deals in United States Vaccines Market
Promising Vaccines in Clinical Development by Major Companies
Key Market Drivers and Inhibitors of the United States Vaccines Market
Major Companies Analysis
The answers to the following key questions can be found in the report:
What is the size of the United States vaccines market during 2015 -2025?
What will be the revenue generated by each vaccine during the forecast period?
Which major vaccine provides highest market share?
How are the overall market and vaccine type growing?
What are the key drivers and inhibitors in the current market?
What will be the impact of drivers and inhibitors in the future?
What are the various vaccines available in the United States?
How is the market predicted to develop in the future?
Who are the key players in this market space?

Epigenetics Market: What will your New Revenue Sources be?

According to a new market research report “Epigenetics Market by Product (Kit, Enzymes, Reagent, NGS, Mass Spectrometer, PCR, Bioinformatics), Application (Oncology, Cardiology, Immunology), Technology (DNA Methylation, Histone Modification), End User (Academic, CRO) – Global Forecast to 2022”, published by MarketsandMarkets™, the market is projected to reach USD 1,605.7 million by 2022 from an estimated USD 854.0 million in 2017, at a CAGR of 13.5% during the forecast period.

Don’t miss out on business opportunities in Epigenetics Market. Speak to our analyst and gain crucial industry insights that will help your business grow:
https://www.marketsandmarkets.com/speaktoanalyst.asp?id=896

The key factors that are driving the growth of this market include The decreasing sequencing costs and time, increase in research activities to identify and develop inhibitors/drugs for various diseases, funding for epigenetics research, and rising prevalence of cancer.

Growing applications in Personalized Medicine and Targeted Therapy in Oncology is a growth opportunity for the Epigenetics market

According to a press release published by the Tufts Center for the Study of Drug Development in May 2015, biopharmaceutical companies have nearly doubled their R&D investments in personalized medicine over the last five years, and these investments are further expected to increase by 33% over the next five years. This will further drive the use of epigenetics tools. A 2016 study performed to analyze the epigenetic modification of chronic lymphocytic leukemia (CLL) in the patient population fueled interest in prognostic biomarkers and personalized therapies. This study was performed by CeMM Research Center for Molecular Medicine of the Austrian Academy of Science (Austria) in collaboration with the University of Southampton and the Royal Bournemouth Hospital under the European BLUEPRINT project and the International Human Epigenome Consortium. The expanding application of epigenetics in personalized medicine and targeted therapies, therefore, offers significant opportunities for market growth.

Browse and in-depth TOC on “Epigenetics Market”

191 – Tables

37 – Figures

230 – Pages

View more detailed TOC @

https://www.marketsandmarkets.com/Market-Reports/epigenetics-technologies-market-896.html

Among the Application Segments, Oncology Dominated the Global Epigenetics Market in 2016

Based on application, the oncology segment accounted for the largest share of the Epigenetics Market in 2016. The large share of this segment can be attributed to the rising prevalence of cancer and the increasing number of research-related activities.

DNA Methylation Segment Dominated the Epigenetics Market, by Technology in 2016

On the basis of technology, the Epigenetics Market is segmented into DNA methylation, histone modifications, and other technologies (includes non-coding RNA and chromatin remodeling). The DNA methylation segment accounted for the largest share of the Global Epigenetics Market in 2016. The large share of this segment is attributed to the increasing incidence of cancer and the ability of this technique to study different types of cancer with quality outcomes.

North America Dominated the Global Epigenetics Market in 2016

North America accounted for the largest share of the Epigenetics Market in 2016, followed by Europe. Increase in epigenetics research activities, favorable government funding initiatives, high R&D expenditure, rising incidence of various diseases, and the presence of key players in the region are the key factors driving the growth of the Epigenetics Market in North America.

Request for Free Sample Report @ https://www.marketsandmarkets.com/requestsample.asp?id=896

Non-Invasive Prenatal Testing Market

The Potential Non-Invasive Prenatal Testing(NIPT) Market is expected to reach more than USD 4 Billion across the 15 major markets(15MM) by the year end of 2021.

More Information @ http://www.dpiresearch.com/page_info.php?P_ID=50

Long–term Growth Projection:

More than 2.5 Million tests will be conducted by the 11 major NIPT test by the year end of 2021.

Non-Invasive Prenatal Testing (NIPT) market size was valued at nearly USD 1 Billion in 2016 and market is expected to grow at the CAGR of XX% during 2017-2021.

Market growth can be attributed to factors such as high incidence rate of babies born with Down syndrome, no risk of miscarriage with NIPT and shifting trend towards child bearing at advanced maternal age (35 years or older). With increased patient access to NIPT test, the NIPT test market is anticipated to have a positive outlook in the coming years. High test cost, strict regulatory requirements and ethical hurdles is restraining the growth of NIPT test market.

NIPT Test Market: Test–wise Outlook

Natera Panorama test will lead the NIPT test market with the market share of more than 25% by the year end of 2021.MaterniT21 Plus and Bambini test have shown its potential to become 2nd and 3rd popular NIPT test. Harmony test is the fourth leading test in the NIPT test market. NIFTY and Verifi test hold the fifth and sixth highest share of the NIPT test market. Other emerging tests such as Prena, IONA, VisibiliT, Veracity and informaseq NIPT test which is likely to affect the market share during the forecast period.

 

NIPT Test Market: Country–wise Outlook:

United States is the most attractive market with market share of more than 50% in 2016. China will be the second largest market for NIPT test which is expected to grow at a CAGR of XX% by 2021. United Kingdom is expected to be third largest NIPT test market being followed by Germany by the end of the forecasted period.

This is the 3rd edition report on NIPT Test Market by DPI Research.The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry–validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, country wise actual and potential market, NIPT test analysis with volume and market revenue and competitive landscape. The report also covers market growth drivers, challenges, current and upcoming trends of the NIPT test market

 

GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET SEGMENTATION

Global Non-Invasive Prenatal Testing (NIPT) Market – By Test Type

 

1.    MaterniT21 PLUS

2.    Harmony

3.    NIFTY

4.    Verifi

5.    Panorama

6.    PrenaTest

7.    BambniTest

8.    informaSeq

9.    VisibiliT

10.  Veracity

11.  IONA Test

 

Global Non-Invasive Prenatal Testing (NIPT) Market – By Country

 

1.    United States

2.    United Kingdom

3.    Germany

4.    Italy

5.    Spain

6.    France

7.    Switzerland

8.    Sweden

9.    Belgium

10.  Australia

11.  New Zealand

12.  Japan

13.  China

14.  India

15.  Brazil